Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.03. | Institute of BioMedical Research Corp.: MRES: M2Bio Food and Beverage Wraps Up 2023/ 2024 Looking Ahead | 404 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specialising in alternative... ► Artikel lesen | |
01.03. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Provides Corporate Update | 276 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / March 1, 2024 / Institute of Biomedical Research Corporation (OTC PINK:MRES) is pleased to provide further details of the sale to Real American Capital Corporation... ► Artikel lesen | |
23.02. | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Introduces M2BioKids: A Pioneering Approach to Elevating Childhood Health and Development | 501 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 23, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
22.02. | Institute of BioMedical Research Corp.: MRES: M2Enviro 2023 Year-End Review and 2024 Looking Forward | 640 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 22, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology,specializing in alternative... ► Artikel lesen | |
09.02. | Institute of BioMedical Research Corp.: MRES: M2Biome 2023 Year-End Review and 2024 Looking Forward | 378 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / February 9, 2024 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
02.01. | Institute of BioMedical Research Corp.: MRES: M2MMA Gears Up for a Landmark Year in 2024 | 796 | ACCESSWIRE | CAPE TOWN / ACCESSWIRE / January 2, 2024 / CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / January 2, 2024 / Institute of Biomedical Research Corp. (OTC PINK: MRES), a vanguard entity at the forefront of nutraceutical... ► Artikel lesen | |
15.11.23 | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Expands Global Presence with New Offices in Dubai Science Park | 373 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES): A pioneering force in nutraceutical biotechnology, specializing in alternative plant-based... ► Artikel lesen | |
14.11.23 | Institute of BioMedical Research Corp.: MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office | 348 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative... ► Artikel lesen | |
03.11.23 | Institute of BioMedical Research Corp.: African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair | 324 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative... ► Artikel lesen | |
12.10.23 | Institute of BioMedical Research Corp.: M2MMA Announces 2024 Fight Schedule and Appoints CEO | 917 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 12, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
02.10.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Chair, Prof Maharaj, to Deliver Keynote Address on Cutting-Edge Biotechnology Advancements | 470 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / October 2, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative... ► Artikel lesen | |
21.09.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Closes JDAX Acquisition | 512 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 21, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
15.09.23 | Institute of BioMedical Research Corp.: M2Bio Sciences Pharmacology & Clinical Application of CBD | 519 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
13.09.23 | Institute of BioMedical Research Corp.: M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update | 586 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 13, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in... ► Artikel lesen | |
17.08.23 | Institute of BioMedical Research Corp.: M2bio Sciences Announces Launch of Exclusive MMA Organization | 386 | ACCESSWIRE | CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / August 17, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES) ("Institute of Biomedical Research" or the "Company"), a pioneering force in nutraceutical... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,635 | +0,75 % | Biotech Report: Biontech behauptet, Evotec und Qiagen konsolidieren | (shareribs.com) Frankfurt / New York 25.03.2024 - Biotech-Werte zeigen sich zum Wochenauftakt uneinheitlich. Biotest und Biontech können zulegen. Evotec und Qiagen stehen unter Druck. An der Wall Street... ► Artikel lesen | |
EVOTEC | 14,470 | +0,66 % | Evotec, HelloFresh, Lanxess, TUI, Zalando und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
MORPHOSYS | 67,20 | 0,00 % | EQS-News: MorphoSys AG: MorphoSys gibt US-Kartellfreigabe der geplanten Übernahme durch Novartis gemäß HSR Act bekannt | EQS-News: MorphoSys AG
/ Schlagwort(e): Sonstiges
MorphoSys gibt US-Kartellfreigabe der geplanten Übernahme durch Novartis gemäß HSR Act bekannt
22.03.2024 / 07:30 CET/CEST
Für... ► Artikel lesen | |
PRAXIS PRECISION MEDICINES | 61,22 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients | In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with... ► Artikel lesen | |
VIKING THERAPEUTICS | 74,96 | -1,16 % | AKTIONÄR-Hot-Stock Viking Therapeutics: Die Spannung steigt | Innerhalb der Pharma- und Biotechnologie-Branche gilt der Adipositas-Bereich derzeit als besonders heiß. Kein Wunder, boomt das Geschäft mit Wegovy, Zepbound und Co der beiden Marktführer Novo Nordisk... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 9,990 | 0,00 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
BIONTECH | 86,10 | +0,19 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Biontech anlässlich der jüngst präsentierten Quartalszahlen des Impfstoffherstellers von 110 auf 95 US-Dollar gesenkt, die... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 4,160 | +10,93 % | Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment | ||
4D MOLECULAR THERAPEUTICS | 31,460 | -12,29 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen | |
NUVALENT | 75,10 | -2,01 % | Nuvalent, Inc.: Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 | CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... ► Artikel lesen | |
ANNEXON | 7,085 | 0,00 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones | Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 50,34 | +1,33 % | MoonLake Immunotherapeutics AG: MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day | MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
Positive 24-week data from... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 49,840 | -0,52 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
IMMUNOVANT | 31,930 | -1,81 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
BEAM THERAPEUTICS | 33,060 | -2,65 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |